<!doctype html><html lang=en><meta charset=utf-8><meta name=generator content="Hugo 0.78.1"><meta name=viewport content="width=device-width,initial-scale=1,viewport-fit=cover"><meta name=color-scheme content="light dark"><meta name=supported-color-schemes content="light dark"><title>Gadkar 2016&nbsp;&ndash;&nbsp;Papers</title><link rel=stylesheet href=/stevengogogo/PaperNotes/css/core.min.0e6154f1fe5441faaa4f418ca1a607b9f3edbad43b1ab8782737ee279ca2c5a48c8dbe23af3340af50c91a2558bc2b55.css integrity=sha384-DmFU8f5UQfqqT0GMoaYHufPtutQ7Grh4JzfuJ5yixaSMjb4jrzNAr1DJGiVYvCtV><meta name=twitter:card content="summary"><meta name=twitter:title content="Gadkar 2016"><body><section id=header><div class="header wrap"><span class="header left-side"><a class="site home" href=/stevengogogo/PaperNotes/><span class="site name">Papers</span></a></span>
<span class="header right-side"><div class="nav wrap"><nav class=nav><a class="nav item" href=/stevengogogo/PaperNotes/categories/>Categories</a><a class="nav item" href=/stevengogogo/PaperNotes/tags/>Tags</a></nav></div></span></div><div class="site slogan"><span class=title>Collection of papers I read</span></div></section><section id=content><div class=article-container><section class="article header"><h1 class="article title">Gadkar 2016</h1><p class="article date">2020-10-22</p></section><article class="article markdown-body"><p><a href=https://sciwheel.com/work/#/items/4692057 target=_blank>Sciwheel</a>.</p><p><a href=https://www.sciencedirect.com/science/article/pii/S1740674916300336?via%3Dihub target=_blank>Article</a></p><h2 id=introduction>Introduction</h2><ul><li>drug development in the &lsquo;post-genomic era&rsquo; => data science</li><li>majority of Phase II and Phase III clinical trial failures are due to <strong>lack of efficacy</strong></li><li>more confidence in the <strong>mechanism of action</strong> is crucial for drug development in the early phase</li><li>most novel drug mechanisms, however, human evidence is minimal if not absent during preclinical development</li><li>In vitro: target & biomarkers</li><li>In vivo (animal models): interspecies differences in physiology and pathology</li><li>In silico (math modeling): pharmacokineticâ€“pharmacodynamic (PKPD), but not complex, highly regulated biology and disease in animals or humans typically.</li><li>Quantitative Systems Pharmacology (QSP):<ul><li>Quantitative analysis of the dynamic interactions between drug(s) and a biological system that aims to understand the behavior of the system as a whole, as opposed to the behavior of its individual constituents</li><li>Data-driven models to mechanistically driven ones</li><li>Numerous potential applications of QSP exist in the preclinical and translational space
<img src=https://user-images.githubusercontent.com/40054455/86617645-26a7b900-bfea-11ea-8e03-713aaf88de95.PNG alt=fig1></li></ul></li></ul><h2 id=evaluation-of-a-novel-target-for-treatment-of-asthma>Evaluation of a novel target for treatment of asthma</h2><ul><li>Agents targeting IgE (omalizumab) and IL-5 (mepolizumab) have been approved, and other agents targeting the IL-5, IL-4, and IL-13 cytokine pathways are in advanced development</li><li>complex redundancy, feedback, and regulation of the numerous cells, pathways, and functions
<img src=https://user-images.githubusercontent.com/40054455/86617661-2b6c6d00-bfea-11ea-9574-dd967c3afcac.PNG alt=tbl1></li><li>mechanistic information collated from expert knowledge and in vitro and preclinical data.</li><li>Blinded predictions for response of severe asthmatic virtual patients to the anti-IL4R a antagonist (dupilumab) matched clinical results well => useful</li><li>bridges complex mechanistic interactions and clinical knowledge to enable predictive simulations and exploration</li></ul><p><img src=https://user-images.githubusercontent.com/40054455/86617653-290a1300-bfea-11ea-9f5c-f0b4af1be9d3.PNG alt=fig2></p><h2 id=mechanistic-support-and-combination-strategy-for-erk-inhibition-in-braf-mutant-cancer>Mechanistic support and combination strategy for ERK inhibition in BRAF mutant cancer</h2><ul><li>mitogen-activated protein kinase (MAPK) signaling cascade, consisting of the RAS/RAF/MEK/ERK constitutively activated in many human cancers</li><li>Inhibitors targeting BRAF (vemurafenib, dabrafenib) and MEK (cobimetinib, trametinib) are approved</li><li>But there are poor response or acquired resistence</li><li>acquired resistance to BRAF or MEK inhibitors show pathway rebound and remain responsive to <strong>ERK inhibition</strong>
<img src=https://user-images.githubusercontent.com/40054455/86617655-2a3b4000-bfea-11ea-9609-a77c39e79cb2.PNG alt=fig3></li><li>weighted virtual populations were then used to predict response rates to the ERK-inhibitor regimens, for which clinical data did not yet exist.</li><li>predicted a synergistic response to the combination of MEK + ERK inhibition</li></ul><h2 id=pbpk-guidance-for-intravenously-administration-of-oseltamivir-tamiflu-in-pediatric-patients-children>PBPK guidance for intravenously administration of oseltamivir (Tamiflu) in pediatric patients (children)</h2><ul><li>allow simulations of the concentration versus time profiles in plasma and tissues after dosing.</li><li>superior predictive power achieved through translation of in vitro data into expected in vivo performance, well-suited to translational predictions</li><li>streamline late stage drug development with avoidance of routine clinical studies
<img src=https://user-images.githubusercontent.com/40054455/86617656-2ad3d680-bfea-11ea-84e4-cf880978cb43.PNG alt=fig5></li><li>Drug distributions and metabolism as well as age dependency</li><li>In vivo, verified the reliability and plausibility of the modeling of oral and intravenous dosing in newborn monkeys => verification of simulations of oral dosing in infants and neonates</li></ul><h2 id=summary>Summary</h2><p>Values of QSP:</p><ol><li>identifying novel targets</li><li>guiding preclinical study design</li><li>predicting clinical PK based on physiological and molecule considerations</li><li>predicting the potential for human efficacy and safety of novel targets and compounds</li><li>evaluating or identifying potential biomarkers</li><li>providing mechanistic understanding of efficacy, safety, and biomarkers</li><li>evaluating combination therapy strategies for new molecules.</li></ol><h2 id=reference>Reference</h2></article><section class="article author"><p class=name>Shao-Ting Chiu</p><div class=details><a class=item href=https://github.com/stevengogogo target=_blank><span class="iconfont icon-github"></span>&nbsp;stevengogogo</a></div></section></div><div class="article bottom"><section class="article navigation"><p><a class=link href=/stevengogogo/PaperNotes/posts/garcia-2016/><span class="iconfont icon-article"></span>Garcia 2016</a></p><p><a class=link href=/stevengogogo/PaperNotes/posts/foteinou-2015/><span class="iconfont icon-article"></span>Foteinou 2015</a></p></section></div></section><section id=footer><div class=footer-wrap><p class=copyright>Papers</p><p class=powerby><span>Powered&nbsp;by&nbsp;</span><a href=https://gohugo.io target=_blank>Hugo</a><span>&nbsp;&&nbsp;</span><a href=https://themes.gohugo.io/hugo-notepadium/ target=_blank>Notepadium</a></p></div></section><link rel=stylesheet href=https://cdn.jsdelivr.net/npm/katex@0.11.1/dist/katex.min.css integrity=sha384-zB1R0rpPzHqg7Kpt0Aljp8JPLqbXI3bhnPWROx27a9N0Ll6ZP/+DiW/UqRcLbRjq crossorigin=anonymous><script defer src=https://cdn.jsdelivr.net/npm/katex@0.11.1/dist/katex.min.js integrity=sha384-y23I5Q6l+B6vatafAwxRu/0oK/79VlbSz7Q9aiSZUvyWYIYsd+qj+o24G5ZU2zJz crossorigin=anonymous></script><script defer src=https://cdn.jsdelivr.net/npm/katex@0.11.1/dist/contrib/auto-render.min.js integrity=sha384-kWPLUVMOks5AQFrykwIup5lo0m3iMkkHrD0uJ4H5cjeGihAutqP0yW0J6dpFiVkI crossorigin=anonymous onload=renderMathInElement(document.body);></script></body></html>